Terns Pharmaceuticals touts safety data from an ex-Eli Lilly candidate in the hunt for NASH treatment

While many others have tried — and failed — to get a NASH candidate across the finish line, Terns Pharmaceuticals thinks its FXR agonist will eventually earn its wings without the safety issues that have slowed others down. Now, a mid-stage safety readout could help add some validity to those hopes.